Sbir topic 118: reagents for immunologic analysis of non-mammalian and underrepresented mammalian models.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93023C00039
- Awardee
-
Silver Lake Research Corporation UEI C9FZMJCTQFP4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $750,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20231 · Posted Jul 20, 2022
- Contract value 100% obligated
- $750,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 13 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Irwindale, CA, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $750,000 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $750,000 firm fixed-price contract to Silver Lake Research Corporation, a small business located in Irwindale, California, under SBIR Topic 118 focused on developing reagents for immunologic analysis of non-mammalian and underrepresented mammalian models. The contract, which carries a total small business set-aside designation, was awarded on September 1, 2023, with an ultimate completion date of August 31, 2026. Silver Lake Research Corporation, known for its expertise in monoclonal antibody development and rapid testing innovations, will leverage this funding to advance immunologic research tools that support infectious disease detection and analysis in animal models not typically addressed by standard reagent suppliers.
This award represents part of NIAID's broader Small Business Innovation Research (SBIR) program initiative, which aims to stimulate technological innovation and strengthen small business participation in meeting federal research needs. Silver Lake Research Corporation's established track record in developing monoclonal antibodies and assays for infectious disease applications positions the company well to deliver the specialized reagents required under this contract. The funding will support research and development activities designed to expand the toolkit available for scientists conducting immunologic studies in diverse animal models, ultimately contributing to NIAID's mission of combating infectious diseases and allergic conditions.
Quick answers
Who was awarded contract 75N93023C00039?
75N93023C00039 was awarded to Silver Lake Research Corporation by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 26, 2023.
How much is contract 75N93023C00039 worth?
The government has obligated $750,000 on 75N93023C00039.
Was contract 75N93023C00039 competed?
The extent of competition for 75N93023C00039 was full and open competition after exclusion of sources. The government received 13 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award